A prospective, randomized, controlled, multicenter clinical study on the intervention of indolent lymphoma with the "Jieduxiaoluo Formula"

INTERVENTION: Treatment group:Differential Diagnosis and Treatment Based on Typology;Control group:Watch and wait; CONDITION: Indolent Lymphoma PRIMARY OUTCOME: Overall survival; SECONDARY OUTCOME: Progression‐free survival;Cytokine;Lymphocyte subsets;Genetic fragment variation;Hotspot gene mutations;Chromosome karyotype; INCLUSION CRITERIA: I. Age range: 18 ‐ 80 years old, gender not restricted. Before inclusion, informed consent must be signed; II. According to the NCCN 2024 guidelines, the diagnosis through histopathology is clear: chronic lymphocytic leukemia / small B‐cell lymphoma, follicular lymphoma, mantle cell lymphoma, and patients who can undergo observation and waiting; III. There are measurable and assessable lesions for efficacy evaluation, and the expected survival period is more than 4 months.